{"id":10420,"date":"2013-01-22T19:48:01","date_gmt":"2013-01-22T19:48:01","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/rbcc-visits-texas-genome-mapping-target\/"},"modified":"2013-01-22T19:48:01","modified_gmt":"2013-01-22T19:48:01","slug":"rbcc-visits-texas-genome-mapping-target","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/genome\/rbcc-visits-texas-genome-mapping-target\/","title":{"rendered":"RBCC Visits Texas Genome-Mapping Target"},"content":{"rendered":"<p><p>    NOKOMIS, Fla.--(BUSINESS WIRE)--  <\/p>\n<p>    Since the new year began, Rainbow Coral Corp. (RBCC)    has wasted no time in searching for new targets to add to its    portfolio of projects for commercialization. Last week, the    Companys executive leadership accepted an invitation to tour a    genome-mapping facility in Houston with which RBCC could soon    partner.  <\/p>\n<p>    New healthcare innovations related to the human genome    represent a target-rich area of interest for RBCC.The    Texas company currently being reviewed performs tests to    identify genetic markers in patients that can potentially boost    or nullify the effects of certain medications.  <\/p>\n<p>    Such testing could dramatically change the way medications are    prescribed, potentially fostering a significant reduction in    global health care costs.  <\/p>\n<p>    Knowing specifics about an individuals genetic make-up can    greatly assist a patients doctor in determining correct doses    of medications as well as ruling out medications that could    prove harmful, said RBCC CEO Patrick Brown. Genome mapping    opens up a host of new possibilities for doctors and patients    alike, and were very interested in the technologys economic    potential.  <\/p>\n<p>    As the company searches for its next partner, RBCCs biotech    subsidiary Rainbow Biosciences remains close to a joint venture    deal with Amarantus Bioscience, makers of exciting new    diagnostic tools and therapies for neurological diseases such    as Parkinsons.  <\/p>\n<p>    Amarantus recently announced highly promising results in new    animal trials of its forthcoming Parkinsons therapeutic, known    as MANF.  <\/p>\n<p>    For more information on RBCC and its biotechnology targets,    please visitwww.rainbowbiosciences.com\/investors.  <\/p>\n<p>    Rainbow BioSciences is dedicated to developing new medical and    research technology innovations to compete alongside companies    such as Amgen Inc. (AMGN),    Cell Therapeutics, Inc. (CTIC)    and Abbott Laboratories (ABT).  <\/p>\n<p>    Follow us on Twitter atwww.twitter.com\/RBCCinfo.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read more here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/rbcc-visits-texas-genome-mapping-100000474.html;_ylt=A2KJ3Cbt7P5QhygACHL_wgt.\" title=\"RBCC Visits Texas Genome-Mapping Target\">RBCC Visits Texas Genome-Mapping Target<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> NOKOMIS, Fla.--(BUSINESS WIRE)-- Since the new year began, Rainbow Coral Corp. (RBCC) has wasted no time in searching for new targets to add to its portfolio of projects for commercialization <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/genome\/rbcc-visits-texas-genome-mapping-target\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-10420","post","type-post","status-publish","format-standard","hentry","category-genome"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/10420"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=10420"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/10420\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=10420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=10420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=10420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}